The Sudden Drop of Novo Nordisk: A Cautionary Tale for Big Pharma's Expansion Plans The recent market value wipeout of over $30 billion by Novo Nordisk should serve as a stark reminder to pharmaceutical companies that even the most promising experimental drugs can fall short.
On Friday, the Danish drugmaker's shares plummeted 9.
3%, marking the largest intraday loss since February, after announcing that its late stage trial for ziltivekimab failed to achieve its primary goal of reducing major adverse cardiovascular events.